<table>
<thead>
<tr>
<th>Study (Reference)</th>
<th>Disease End Point</th>
<th>Study Supplement</th>
<th>Participants, n</th>
<th>Disease Events, n</th>
<th>Incidence of Disease End Point, n per 1000 persons</th>
<th>Prevalence of Disease End Point, %</th>
<th>Unadjusted Relative Risk (95% CI)</th>
<th>Unadjusted Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linxian General Population Trial (21)</td>
<td>Death from stroke</td>
<td>Retinol + zinc + riboflavin + niacin vs. placebo</td>
<td>29,584†</td>
<td>–</td>
<td>–</td>
<td>66</td>
<td>77</td>
<td>3.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Retinol + zinc + vitamin C + molybdenum vs. placebo</td>
<td></td>
<td>71</td>
<td>77</td>
<td>3.8</td>
<td>4.1</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Retinol + zinc + β-carotene + selenium + α-tocopherol vs. placebo</td>
<td></td>
<td>55</td>
<td>77</td>
<td>2.9</td>
<td>4.1</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Riboflavin + niacin + vitamin C + molybdenum vs. placebo</td>
<td></td>
<td>60</td>
<td>77</td>
<td>3.2</td>
<td>4.1</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Riboflavin + niacin + β-carotene + selenium + α-tocopherol vs. placebo</td>
<td></td>
<td>58</td>
<td>77</td>
<td>3.1</td>
<td>4.1</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vitamin C + molybdenum + β-carotene + selenium + α-tocopherol vs. placebo</td>
<td></td>
<td>67</td>
<td>77</td>
<td>3.6</td>
<td>4.1</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Retinol + zinc + riboflavin + niacin + vitamin C + molybdenum + β-carotene + selenium + α-tocopherol vs. placebo</td>
<td></td>
<td>69</td>
<td>77</td>
<td>3.7</td>
<td>4.1</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Retinol + zinc</td>
<td></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Riboflavin + niacin</td>
<td></td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Continued on following page
<table>
<thead>
<tr>
<th>Study (Reference)</th>
<th>Unadjusted Relative Risk (95% CI)</th>
<th>Unadjusted Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retinol + molybdenum vs. placebo</td>
<td>Isolated systolic: 1.11 (0.88–1.41)</td>
<td>-</td>
</tr>
<tr>
<td>Retinol + molybdenum vs. placebo</td>
<td>Isolated diastolic: 0.94 (0.70–1.26)</td>
<td>-</td>
</tr>
<tr>
<td>Retinol + molybdenum vs. placebo</td>
<td>Both systolic and diastolic: 0.93 (0.74–1.16)</td>
<td>-</td>
</tr>
<tr>
<td>Retinol + molybdenum vs. placebo</td>
<td>Isolated systolic: 1.07 (0.85–1.36)</td>
<td>-</td>
</tr>
<tr>
<td>Retinol + molybdenum vs. placebo</td>
<td>Isolated diastolic: 1.23 (0.93–1.62)</td>
<td>-</td>
</tr>
<tr>
<td>Retinol + molybdenum vs. placebo</td>
<td>Both systolic and diastolic: 1.01 (0.81–1.26)</td>
<td>-</td>
</tr>
</tbody>
</table>

...
<table>
<thead>
<tr>
<th>Participants, n</th>
<th>Disease Events, n</th>
<th>Incidence of Disease End Point, per 1000 persons</th>
<th>Unadjusted Relative Risk (95% CI)</th>
<th>Unadjusted Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Received Supplements with Specified Nutrients</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>molybdenum</td>
<td>-carotene</td>
<td>selenium</td>
<td>-tocopherol</td>
</tr>
<tr>
<td>Isolated systolic:</td>
<td>1.07 (0.96–1.21)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isolated diastolic:</td>
<td>1.13 (0.98–1.27)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Both systolic and diastolic:</td>
<td>1.05 (0.92–1.19)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Received Supplements without Specified Nutrients</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C</td>
<td>molybdenum</td>
<td>-carotene</td>
<td>selenium</td>
<td>-tocopherol</td>
</tr>
<tr>
<td>Isolated systolic:</td>
<td>1.08 (0.96–1.21)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isolated diastolic:</td>
<td>1.06 (0.89–1.27)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Both systolic and diastolic:</td>
<td>0.88 (0.76–1.02)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continued on following page:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Appendix Table 2—Continued

<table>
<thead>
<tr>
<th>Study (Reference)</th>
<th>Disease End Point</th>
<th>Study Supplement</th>
<th>Participants, n</th>
<th>Disease Events, n</th>
<th>Incidence of Disease End Point, n per 1000 persons</th>
<th>Prevalence of Disease End Point, %</th>
<th>Unadjusted Relative Risk (95% CI)</th>
<th>Unadjusted Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Total</td>
<td>Received Supplements with Specified Nutrients</td>
<td>Received Supplements without Specified Nutrients</td>
<td>Total</td>
<td>Received Supplements with Specified Nutrients</td>
<td>Received Supplements without Specified Nutrients</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Total: 6364</td>
<td>-</td>
<td>6377</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Isolated systolic: 0.95 (0.85–1.08)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Isolated diastolic: 0.84 (0.73–0.98)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Both systolic and diastolic: 1.05 (0.94–1.18)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Isolated systolic: 0.94 (0.84–1.07)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Isolated diastolic: 0.95 (0.82–1.10)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Both systolic and diastolic: 0.89 (0.79–0.99)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Isolated systolic: 0.93 (0.83–1.05)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Isolated diastolic: 1.23 (1.06–1.42)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Both systolic and diastolic: 0.98 (0.87–1.09)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SU.VI.MAX (23)</td>
<td>Ischemic cardiovascular disease incidence</td>
<td>Vitamin C + vitamin E + (\beta)-carotene + zinc vs. placebo</td>
<td>6364</td>
<td>6377</td>
<td>134</td>
<td>137</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SU.VI.MAX (25)</td>
<td>Hypertension†</td>
<td>Vitamin C + vitamin E + (\beta)-carotene + selenium + zinc vs. placebo</td>
<td>Women</td>
<td>1502</td>
<td>1431</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Year 1: 19.4</td>
<td>Year 1: 20.8</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Year 6: 34.6</td>
<td>Year 6: 32.4</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Year 6: 54.6</td>
<td>Year 6: 53.8</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* Comparisons were made between the groups receiving the combination of the listed nutrients and groups receiving combinations of placebo or nutrients other than the nutrients listed. – = not reported; SU.VI.MAX = SUPple´mentation en VItamines et Mine´raux AntioXydants.
† The number of participants in each randomized group was not reported.
‡ Defined as systolic blood pressure ≥ 140 mm Hg, diastolic blood pressure ≥ 90 mm Hg, or antihypertensive drug use at the end of the study.